Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Stock Up 2.7%

Shares of ORKA stock traded up $2.92 during mid-day trading on Friday, reaching $111.04. The company’s stock had a trading volume of 1,047,380 shares, compared to its average volume of 1,138,555. The firm has a market capitalization of $7.35 billion, a PE ratio of -54.70 and a beta of -0.34. The company’s 50 day simple moving average is $86.50 and its 200-day simple moving average is $62.27. Oruka Therapeutics, Inc. has a 12-month low of $14.08 and a 12-month high of $111.37.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ORKA. Legal & General Group Plc purchased a new position in Oruka Therapeutics in the second quarter valued at about $28,000. BNP Paribas Financial Markets increased its holdings in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada raised its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ORKA shares. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 3rd. UBS Group boosted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.